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Background: Studies indicate that mild to moderate iodine deficiency in pregnancy may have a long-term
negative impact on child neurodevelopment. These effects are likely mediated via changes in maternal thyroid
function, since iodine is essential for the production of thyroid hormones. However, the impact of iodine avail-
ability on thyroid function during pregnancy and on thyroid function reference ranges are understudied. The aim
of this study was to investigate the association between iodine intake and thyroid function during pregnancy.
Design: In a population-based pregnancy cohort including 2910 pregnant women participating in The Norwegian
Mother and Child Cohort Study, we explored cross sectional associations of maternal iodine intake measured (1)
by a food frequency questionnaire and (2) as iodine concentration in a spot urine sample, with plasma thyroid
hormones and antibodies.
Results: Biological samples were collected in mean gestational week 18.5 (standard deviation 1.3) and diet was
assessed in gestational week 22. Median iodine intake from food was 121lg/day (interquartile range 90, 160), and
40% reported use of iodine-containing supplements in pregnancy. Median urinary iodine concentration (UIC) was
59lg/L among those who did not use supplements and 98lg/L in the women reporting current use at the time of
sampling, indicating mild to moderate iodine deficiency in both groups. Iodine intake as measured by the food
frequency questionnaire was not associated with the outcome measures, while UIC was inversely associated with
FT3 ( p= 0.002) and FT4 ( p< 0.001). Introduction of an iodine-containing supplement after gestational week 12
was associated with indications of lower thyroid hormone production (lower FT4, p= 0.027, and nonsignificantly
lower FT3, p= 0.17). The 2.5th and 97.5th percentiles of TSH, FT4, and FT3 were not significantly different by
groups defined by calculated iodine intake or by UIC.
Conclusion: The results indicate that mild to moderate iodine deficiency affect thyroid function in pregnancy.
However, the differences were small, suggesting that normal reference ranges can be determined based on data also
from mildly iodine deficient populations, but this needs to be further studied. Introducing an iodine-containing
supplement might temporarily inhibit thyroid hormone production and/or release.
Keywords: iodine, pregnancy, thyroid function, dietary supplements, The Norwegian Mother and Child Cohort
Study, MoBa
Introduction
Results from observational studies, including theNorwegian Mother and Child Cohort Study (MoBa),
have indicated that even mild to moderate iodine deficiency
(ID) in pregnancy might negatively affect child neurodeve-
lopment (1–4). Iodine is an essential micronutrient, as it is an
integral part of the thyroid hormones thyroxine (T4) and
triiodothyronine (T3). Severe ID results in depleted iodine
stores and a failure to sustain normal thyroid hormone levels
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(5). The fetus is entirely dependent on an adequate and stable
supply of these hormones, especially during the first half of
pregnancy, until the fetal thyroid gland is developed. Thyroid
hormones are essential in fetal growth, and particularly for
cells in the central nervous system and for the structural and
functional development of the brain (6). In areas with chronic
moderate to severe ID, children score an estimated 8–10
points lower on IQ tests (7). Other dietary factors may con-
tribute to aggravate symptoms of ID. Examples are defi-
ciencies of other nutrients that are important for thyroid
function (e.g., selenium and iron) (8), and intake of crucif-
erous vegetables that are known to inhibit iodine uptake and
utilization by the thyroid due to high content of thiocyanate
(9). Excessive iodine intake during pregnancy may also result
in thyroid hypofunction (10). The association of iodine intake
with thyroid function is U-shaped, and studies indicate that
the range of optimal intake is narrow (11).
The recommended daily intake of iodine for pregnant
women varies somewhat. The World Health Organization
(WHO) recommends 250lg/day (or a population median
urinary iodine concentration (UIC) ‡150lg/L), which is al-
most 70% higher than that of nonpregnant women, to com-
pensate both for an increased turnover of iodine in pregnancy
and depleted iodine stores in many populations (12). The
European Food Safety Authority has a lower recommenda-
tion of 200lg/day but states that it is for populations with
adequate iodine status prior to conception (13). The Nordic
recommendation is even lower, at 175 lg/day (14), while in
the United States, the recommended daily intake is 220lg/day
and the estimated average requirement is 160lg/day (15,16).
These recommendations are based only on limited data be-
cause the association of iodine intake with thyroid function
during pregnancy has remained understudied. However, all the
above-mentioned recommendations unanimously recommend
150lg/day for nonpregnant women (12–15).
During pregnancy, thyroid hormone production increases
in order to meet the needs of the mother and fetus. Thus,
thyroid hormone concentrations in pregnant women differ
from nonpregnant women, and also change considerably
throughout the gestation period (15). Other important de-
terminants of measured hormone levels are body mass index
(BMI), ethnicity, smoking habits, thyroid autoimmunity, and
method of analysis, especially for free thyroid hormones (17).
The 2017 guidelines of the American Thyroid Association
(ATA) recommend using population- and assay-specific
reference ranges for the thyroid hormones in defining di-
agnostic criteria for thyroid disorders and to avoid basing
reference values on ID populations (15). However, there is a
lack of knowledge regarding the potential impact of mild to
moderate ID on thyroid hormone reference ranges (i.e., the
2.5–97.5 % range) (17).
According to the World Health Organization (18), iodine
supplements should be recommended for pregnant women in
areas of inadequate iodine intake. Although the majority of
US pregnant women have a sufficient iodine intake, the ATA
recommends that all pregnant and lactating women in the
United States use iodine supplements (19). Yet, there is un-
certainty regarding the benefit and safety of recommending
iodine supplements for pregnant women in areas with mild to
moderate ID (20). In severe ID, iodine supplementation re-
duces the risk of thyroid hypofunction, but in mild to mod-
erate ID, results from studies are not consistent (5). Some
studies indicate that iodine supplementation may result in a
temporary ‘‘stunning effect’’ of the thyroid gland with a
transient lower thyroid hormone production (21,22). Other
studies find that supplements may be beneficial or have no
effect on thyroid function or child outcomes (20,23–25). In
MoBa, maternal iodine supplement use initiated in pregnancy
was related to increased risk of child behavior problems and
ADHD (3,4), but not to language or motor development (3).
In a population of pregnant women from a mild to mod-
erately ID population we aimed to
1. Study the associations of iodine intake measured by (i)
a food frequency questionnaire (FFQ) and (ii) by uri-
nary iodine concentration (UIC), with biomarkers of
thyroid function;
2. Define thyroid function reference ranges for thyrotro-
pin (TSH), FT4, and FT3 and investigate whether
these differ according to iodine intake; and
3. Investigate the impact of current iodine supplement
use, and also of timing of initiation, on thyroid func-
tion and autoimmunity.
Subjects and Methods
Subjects and design
This study is embedded within MoBa eTox, a substudy of
the prospective population-based pregnancy cohort MoBa
conducted by the Norwegian Institute of Public Health (26).
Pregnant women in their first trimester were recruited from
all over Norway during the years 1999 to 2008 and asked to
answer questionnaires (in Norwegian) at regular intervals
during pregnancy and after delivery. More than 99% of
participants are of Caucasian origin. Pregnancy and birth
records from theMedical Birth Registry of Norway are linked
to the MoBa database (27). The women consented to par-
ticipation in 41% of the pregnancies. The cohort now in-
cludes 114,500 children, 95,200 mothers, and 75,200 fathers.
The current study is based on version 10 of the quality-
assured data files released for research in 2017.
The participants in MoBa eTox (n = 2999) is a selected
sample of MoBa consisting of participants who had re-
sponded to all questionnaires in MoBa up to child’s age 3
years and had delivered all biological samples in mid
pregnancy and at birth. Only singleton pregnancies were
included. Children with autism, suspected autism, or symp-
toms of severe language delay were reserved for another
substudy and those mother-child pairs were thus not included
in MoBa eTox.
For our study (n= 2910), we additionally excluded women
reporting use of thyroid medication in pregnancy (gestational
week 0–24), and women with calculated energy intakes <4.5
MJ or >20MJ or more than 3 blank pages in the FFQ (28) (see
flowchart of inclusion in Fig. 1).
Exposure variables – iodine intake and UIC
The MoBa FFQ was specifically designed for the MoBa
study and in use from 2002 (29). It was completed by par-
ticipating women around gestational week (GW) 22, and is a
semi-quantitative questionnaire designed to capture dietary
habits and use of dietary supplements during the first half
of pregnancy. It included questions about intake of 255 food
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items or dishes (28). Intake of specific foods and nutri-
ents were calculated based on standard Norwegian por-
tion sizes, the Norwegian food composition table, analysis
of Norwegian food samples (30,31), and data on the content
of more than 1000 dietary supplements collected from
suppliers (32).
As reported previously (3),theMoBa FFQwas shown to be
a valid tool for ranking pregnant women according to high
and low intakes of energy, nutrients, and foods (33). Milk and
seafood are the main dietary sources of iodine in Norway;
thus, iodine intake is highly variable depending on individual
food choices (34). Iodine was validated separately and iodine
intake by the FFQ, including supplemental iodine, showed
good agreement with the reference methods (24 h urinary
iodine excretion and 4 days weighed food diary; triangular
validity coefficient for total iodine intake by the FFQ was
0.62 [95% confidence interval 0.46, 0.77]) (35,36).
Timing of iodine intake from supplements was reported
in the general questionnaires one (GW 17), and three (GW
30). Supplement use was coded in three categories (no use
in pregnancy, current use in GW 17-20, and use reported in
pregnancy but not in GW 17-20). Timing of first report of
iodine-containing supplements was coded in four cate-
gories (never, week 0–26 before pregnancy, GW 0-12, and
GW 13-20).
Blood and urine samples were collected at the routine ul-
trasound examination offered in GW 18 (37). UIC was ex-
plored both as a crude measure (lg/L) and adjusted for
hydration status by the ‘‘residual method’’ (38) (i.e., residuals
after regressing log UIC on log urinary creatinine plus pre-
dicted UIC at the median creatinine concentration, obtaining
UIC adjusted for creatinine [UIC*Cr]). The method is fre-
quently used in nutritional epidemiology to control for
energy-intake in dietary surveys and has also been reported
FIG. 1. Flow chart of inclusion. *TPOAb positive according to manufacturer-defined cutoff for nonpregnant women
(TPOAb >4.11 IU/mL). FFQ, food frequency questionnaire; FT4, free thyroxine; MoBa, Norwegian Mother and Child
Cohort Study; TPOAb, thyroid peroxidase antibodies; TSH, thyrotropin.
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for UIC adjustment (39). UIC*Cr represents an estimate of
UIC at a median hydration state.
Outcome variables: Thyroid function biomarkers
TSH, free T4 (FT4), free T3 (FT3), thyroid peroxidase
antibodies (TPOAb), and thyroglobulin antibodies (TgAb)
were measured in plasma samples frommid pregnancy (mean
gestational week 18.5, standard deviation 1.3). For TPOAb
and TgAb, the 92nd percentile was chosen as a cutoff for
defining antibody positivity based on previous literature (40)
and on exploring associations between measured antibody
concentrations and TSH and FT4 concentrations in our study
sample (Supplementary Figs. S1 and S2; Supplementary Data
are available online at www.liebertpub.com/thy). For TSH,
FT4, and FT3, the cutoffs for defining low and high values
were set to the 2.5th and 97.5th percentiles in a subsample of
TPOAb negative women after exclusion of women that un-
derwent in vitro fertilization (IVF).
Analytical procedures
Samples of urine and blood were collected at the 50 par-
ticipating hospitals, and samples were shipped by ordinary
mail (unrefrigerated shipment) in a vacutainer for long-term
freezing at a central biorepository (37). Storage temperature
was -80C (-20C for whole blood).
UIC was determined at the National Institute for Health
and Welfare (THL) in Helsinki (Finland) by inductively
coupled plasma–mass spectrometry (ICP-MS) using an
Agilent 7800 ICP-MS system (Agilent Technologies Inc.,
Santa Clara, CA). In brief, 100 lL of urine sample was ex-
tracted using ammonium hydroxide solution. Tellurium was
used as an internal standard. On the ICP-MS, m/z = 127 was
scanned for iodine determination. The limit of quantification
of the method was 2lg/L and the linearity was t(r= 0.9999 up
to 1500lg/L). The National Institute of Standards and Tech-
nology standard reference materials SRM2670a (with certified
mass concentration value) and SRM3668 Level 1 and Level 2
were used to validate the method. The coefficient of variation
(CV) of control samples was 3.0–4.8%. The laboratory at THL
participated in the Ensuring the Quality of Urinary Iodine
Procedures Program organized by the Centers for Disease
Control and Prevention three times per year.
Urinary creatinine was analyzed by an enzymatic method
using Multigent Creatinine (Enzymatic) Assay (SENTINEL
CH. Sp.A.) using the ARCHITECT c System (Abbott La-
boratories, Abbott Park, IL) at THL. CV of control samples
was 1.4–1.7%. The laboratory participated in an external
quality assessment scheme for urinary creatinine organized
by Labquality (Finland).
Plasma TSH, FT3, FT4, TPOAb, and TgAb concentrations
were analyzed at THL using chemiluminescent microparticle
immunoassays. Reagents and equipment (Architect ci8200
analyzer) were from Abbott Laboratories. CV of control
samples (Bio-Rad Liquichek Immunoassay Plus lot 40860
high and low level, and in-house control, n = 181) were as
follows: TSH 1.8–2.9%, FT3 2.5–4.7%, FT4 2.7–8.5%,
TPOAb 3.7–5.2%, TgAb 4.1–4.4%. The laboratory partici-
pated in external quality assessment schemes for thyroid
hormones and antibodies organized by Labquality (Finland).
Plasma ferritin was analyzed at THL using a chemilumi-
nescent microparticle immunoassay. The coefficient of var-
iation of control samples (Bio-Rad Liquichek immunoassay
Plus lot 40860 high and low level, and in-house control,
n = 181) were 2.7–3.7%. The laboratory participated in an
external quality assessment scheme for ferritin organized by
Labquality (Finland).
Whole blood selenium was analyzed at Lund University
in Sweden by inductive coupled plasma mass spectrometry
(ICP-MS; iCAP Q, Thermo Fisher Scientific, Bremen,
GmbH) equipped with collision cell with kinetic energy
discrimination and helium as collision gas. The detection
limit was 3.2 lg/L and the coefficient of variation was 1.5%.
The analytical accuracy was verified towards certified ref-
erence material; Seronorm Trace elements whole blood L-1
and L-2 (SERO AS, Billingstad, Norway).
Covariates
Data on covariates were obtained from different sources:
Maternal age at delivery was obtained from theMedical Birth
Registry of Norway. Maternally reported prepregnancy body
weight and height for the calculation of body mass index
(BMI), maternal education (£12, 13–16, ‡17 years), parity
(previous pregnancies ‡22 weeks: 0, 1, ‡2), maternal chronic
illness (asthma, diabetes, inflammatory bowel disease, rheu-
matic disease, epilepsy, multiple sclerosis or cancer before or
during pregnancy [yes/no]), and smoking in pregnancy (aver-
age cigarettes/day GW 0–17) was included from questionnaire
1. Energy intake, fiber intake (as a marker of a healthy dietary
pattern), and intake of cruciferous vegetables (high in gluco-
sinolates, potent goitrogens) were calculated based on the FFQ.
Selenium status (whole blood selenium <80, ‡80lg/L),
and iron status (plasma ferritin <12, 12–29.9, ‡30lg/L) were
measured in the blood samples in mid-pregnancy, and cre-
atinine concentration was measured in the urine samples.
Gestational age at blood and urine sampling was estimated
based on the ultrasound examination, which took place the
same day as the sampling and, if missing, on the first day of
last menstruation.
Ethics
MoBa is conducted according to the guidelines laid down
in the Declaration of Helsinki and written informed consent
was obtained from all participants. MoBa has obtained a
license from the Norwegian Data Inspectorate. The current
study was approved by The Regional Committee for Med-
ical Research Ethics South East Norway 2014/2211.
Statistics
Statistical analyses were performed in STATA (version
15.0; Stata Corp., College Station, TX). The package
postrcspline for STATA was used for graphing of flexible
models (41).
In total, 4.8% of the women had missing values on one
or more of the covariates: pre-pregnancy BMI (n = 54,
1.9%), maternal education (n = 62, 2.1%), gestational age at
sampling (n = 10, 0.3%), and whole blood selenium (n = 18,
0.6%). Missing values in covariates were imputed using
multiple imputation by chained equations in STATA, and
20 imputed datasets were generated for analyses.
Associations between continuous exposures and outcomes
were modelled flexibly by use of restricted cubic splines
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(three knots). Covariates were included in the models based
on previous knowledge and a directed acyclic graph (Sup-
plementary Fig. S3).
Linear regression was used to model associations with
continuous outcomes. To obtain close to normal distribution
of the outcomes, we used the square root of TSH, and we
excluded the highest percentile of FT4 and FT3. Logistic
regressions were used to model the odds of antibody posi-
tivity. Adjusted models included the following covariates:
maternal age, education, parity, pre-pregnancy BMI, fiber
intake, smoking in pregnancy, plasma ferritin, whole blood
selenium, and gestational age at sampling. Urinary creatinine
was included in models with UIC*Cr as exposure, energy
intake in models with iodine from food as exposure, and IVF
in models with supplement use as exposure (supplement use
was more commonly reported in IVF pregnancies).
Possible interaction effects were explored for iodine sup-
plement use, dichotomous variables of whole blood selenium
(<80 lg/L) and plasma ferritin (<20lg/L), intake of crucif-
erous vegetables (>75th percentile), and smoking in preg-
nancy (yes/no). The potential interactions were explored by
including an interaction term with iodine from food in the
spline models.
p-Values are reported for overall associations between
continuous exposures and outcomes by testing the coeffi-
cients of all spline transformations equal to zero. The tests for
nonlinearity were performed by testing the coefficient of the
second spline transformations equal to zero. All statistical
tests were performed on the imputed datasets (n = 20) and
adjusted for random effects of person clusters since some
women participated with more than one pregnancy (n = 9).
Results are reported including robust 95% confidence inter-
vals. A p-value <0.05 was considered statistically significant.
Sensitivity analyses included repeating analyses on thyroid
hormones and TSH, but (1) excluding antibody positive
women, or (2) including the upper first percentile for out-
comes FT3 and FT4.
To explore potential effects of iodine status on population-
specific reference ranges for TSH and thyroid hormones,
we used quantile regression regressing the 2.5th and 97.5th
percentile by categories of UIC, UIC*Cr, and by categories
of iodine intake (restricted to nonusers of iodine supple-
ments) in participants who were not TPOAb-positive (>4.11
IU/mL, cutoff suggested by manufacturer) and not IVF
treated.
Results
Characteristics of the study population are shown in
Table 1. A more detailed overview of population charac-
teristics by exposure level is provided in Supplementary
Table S1.
Iodine intake and UIC
Median habitual iodine intake from food based on the FFQ
was 121lg/day. Four percent had a calculated iodine intake
from food reaching the WHO recommended intake of
250 lg/day for pregnant women, and 30% reaching the re-
commended intake of 150 lg/day for nonpregnant women.
The low intake was reflected in a low median UIC in sup-
plement nonusers (59 lg/L, n = 1738). In this subgroup, io-
dine from food according to the FFQ correlated weakly with
Table 1. Descriptive Characteristics of the Study
Population (n = 2910 Pregnancies)
Study sample/pregnancies, n 2910
Maternal age at delivery (years),
mean (SD)
30.3 (4.2)
Gestational age at sampling
(weeks), mean (SD)
18.5 (1.3)
Prepregnancy BMI (kg/m2), mean (SD) 23.9 (4.0)
Parity, %
0 52
1 33
2 or more 14
Maternal education, %
£12 years 26
13–16 years 47
>16 years 25
Other/missing 2.1
Married/cohabitant, % 98.4
In vitro fertilization, % 2.2
Smoking in pregnancy, %
Occasionally 14
Daily 3.8
Chronic illness, % 8.9
Household income, %
Low 26
Medium 43
High 29
Missing 1.9
Iodine from food (lg/day),
median (IQR)
121 (90, 160)
UIC (lg/L), median (IQR) 68 (35, 116)
Urinary creatinine (g/L), median
(90% range)
0.76 (0.17, 1.92)
UIC (lg/g creatinine), median (IQR) 91 (61, 139)
UIC*Cr (lg/L), median (IQR) 74 (55, 105)
UIC, %
‡150 lg/L (sufficienta) 14
0–150 lg/L (insufficienta) 86
0–100 lg/L 68
0–50 lg/L 37
Plasma FT4 [pmol/L], median
[95% range]
12.6 [10.3, 15.7]
Plasma FT3 [pmol/L], median
[95% range]
4.9 [4.0, 6.0]
Plasma TSH [mU/L], median
[95% range]
1.2 [0.4, 2.9]
Plasma TPOAb positive,b % 8.1
Plasma TgAb positive,b % 7.9
Plasma ferritin (ng/mL), median (IQR) 33 (20, 56)
Empty iron stores
(P-Fe <12 ng/mL), %
9.0
Low iron stores
(P-Fe 12–29.9 ng/mL), %
35
Whole blood selenium (lg/L),
median (IQR)
102 (89, 117)
Low selenium (<80lg/L), % 10
aPopulation median UIC <150lg/L is the recommended cutoff for
defining inadequate iodine intake in pregnancy by the World Health
Organization.
bAntibody positivity was defined as values above the 92nd
percentile (>6.6 IU/mL for TPOAb and >7 IU/mL for TgAb).
IQR, interquartile range; SD, standard deviation; TgAb;
thyroglobulin antibodies; TPOAb, thyroid peroxidase antibodies;
UIC, urinary iodine concentration; UIC*Cr, UIC adjusted for
creatinine.
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spot UIC measured in lg/L (Spearman correlation r = 0.20,
p< 0.001), with UIC measured in lg/g creatinine (Spearman
r= 0.30, p< 0.001), andwithUIC adjusted for creatinine by the
residual method (UIC*Cr) (Spearman r= 0.28, p< 0.001).
The association between iodine from food andUIC in nonusers
of iodine supplements is shown in Figure 2. Habitual iodine
intake explained 3.9% of the variation in UIC ( p< 0.001)
when regressing log iodine from food on log UIC.
The UIC differed according to reported use of iodine-
containing supplements (Supplementary Fig. S4). In participants
reporting supplement use at the time of sampling (GW 17–20,
n=580) median UIC was 98lg/L, significantly higher than in
those not using supplements (median 59lg/L, p< 0.001). There
was no data available on the dosage of current intake of iodine
from supplements, but the most frequently reported supple-
ments contained*150lg per recommended daily dose.
Iodine intake and thyroid function and autoimmunity
Habitual iodine intake from food calculated by the FFQ
was not significantly associated with any of the outcome
measures (Figs. 3 and 4 and Supplementary Fig. S5), but UIC
was inversely associated with FT4 and FT3 (Fig. 3). UIC*Cr
lower than roughly 100lg/L was associated with an increase
in mean FT3. Excluding thyroid antibody positive women
(TPOAb and/or TgAb >92nd percentiles) did not change the
results (Supplementary Fig. S6). Results from crude models
are included in Supplementary Figures 7 and 8.
The results did not differ when taking into account iron
status, selenium status, or smoking during pregnancy. Only
smoking during pregnancy was associated with a lower FT4
and higher FT3 (both p < 0.001). Intake of cruciferous veg-
etables was generally low (median: 18 g/day, 90 percent
range: 2–56 g/day) and was not associated with the thyroid
function parameters.
Population-specific reference ranges
for TSH, FT4, and FT3
Table 2 shows the 2.5th and 97.5th percentiles for plasma
TSH, FT4, and FT3 after excluding TPOAb-positive and
IVF pregnancies. There was no evidence of any association
between either iodine intake or UIC and reference ranges of
plasma TSH, FT4 or FT3 (Table 3 and Supplementary Table
S2). However, even the groups with the highest iodine intakes
had inadequate iodine intake according to the WHO criteria
(i.e., median UIC <150 lg/L). Additionally excluding re-
maining TgAb-positive women (n= 147) did not change the
results (Table 2).
Based on the reference ranges determined in this sub-
group (listed in Table 2), 3.2% of the total study population
had subclinical hypothyroidism (high TSH and normal
FT4), 0.1% had overt hypothyroidism (high TSH and low
FT4), 2.3% had isolated hypothyroxinemia (low FT4 and
normal TSH), 2.3% had subclinical hyperthyroidism (low
TSH and normal FT4), and 0.1% had overt hyperthyroidism
(low TSH and high FT4 or FT3). The prevalence of thyroid
antibody positivity was 11.4% by our population-based
cutoffs at >92nd percentile (i.e., TPOAb >6.6 IU/mL or
TgAb >7 IU/mL).
Iodine from supplements and thyroid function
Forty percent reported use of iodine-containing supplements
in gestational week 0–24, and 20% reported use at the time of
sampling (GW17–20). Current iodine supplement use (yes/no)
was not significantly associated with the outcomes.
Information on timing of iodine supplement use was spec-
ified by 74% of the users of iodine-containing supplements in
pregnancy. Of these, 40% (n= 347) reported first use in weeks
1–26 before conception, 37% (n= 323) in first trimester, and
22% (n= 194) in gestational weeks 13–20.Measures of thyroid
parameters by timing of supplement use are shown in Figure 5
and Supplementary Figure S9. A recent initiation of supple-
ment use (after GW12) was associated with a lower mean FT4
(beta=-0.21, p= 0.027), and also lower FT3 and higher TSH,
but not statistically significant (beta -0.05, p= 0.17 and beta
0.02, p= 0.27) compared with nonuse of supplements. There
was also a tendency of a higher risk of hypothyroxinemia (i.e.,
plasma FT4< 10.3 pmol/L, the population specific reference
range) (odds ratio 2.09, p= 0.089). Results from crude models
are included in Supplementary Figure S10.
Discussion
In this mildly to moderately iodine deficient pregnant
population, we show that a higher UIC was associated with a
slightly lowered FT4 concentration and that a low UIC, from
a cutoff point of roughly 100 lg/L, was associated with an
elevated FT3. Furthermore, we show that reference ranges for
TSH, FT4 or FT3 did not differ by UIC or by calculated
habitual iodine intake. A recent introduction of an iodine
containing supplement was associated with a lower thyroid
function, whereas more long-term use was not (i.e., use ini-
tiated before conception or early in the pregnancy).
Calculated iodine intake and UIC
Calculated habitual iodine intake from food in nonusers of
supplements explained only 4% of the variation in UIC,
FIG. 2. Association between iodine from food (measured
by the food frequency questionnaire covering gestational
weeks 0–22) and spot UIC measured at mean gestational
week 18.5 (SD 1.2) in nonusers of iodine supplements
(n = 1738). The solid line represents the estimated median,
the dotted line shows the 90th percentile, and shaded areas
are the 95% confidence intervals. The predicted values were
estimated by quantile regression adjusting for calculated
energy intake. The histogram illustrates the distribution of
iodine intake from food. UIC, urinary iodine concentration.
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which highlights the restricted value of a spot UIC as a mea-
sure of habitual iodine intake at an individual level. However,
both the median UIC and the variance in UIC increased with
calculated habitual iodine intake (Fig. 2), affirming that the
MoBa FFQ provides a valid measure of the habitual iodine
intake as reported previously (36). The increase inmedianUIC
started to level off at about 150lg/L (equivalent to the 70th
percentile), indicating overreporting of food intake at higher
levels. Median UIC remained below 100lg/L over the whole
range of calculated iodine intakes by the FFQ, thus the whole
FIG. 3. Adjusted associations betweenUIC (column 1; n=2900), creatinine-adjustedUIC (column 2; n= 2900), and iodine from
food (column 3, restricted to nonusers of iodine supplement; n= 1730) and TSH, FT4, and FT3. For TSH, the geometric mean was
modelled (bysquare root transformation), and forFT3andFT4, thehighestfirstpercentilewasexcluded toobtain*normaldistribution.
Including the upper first percentile of FT3 and FT4 did not change the results (Supplementary Fig. S5). FT3, free triiodothyronine.
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group of supplement nonusers in this study had an insufficient
habitual iodine intake in pregnancy (i.e., population median
UIC <150lg/L). Even the women reporting current use of
iodine-containing supplements had median UIC <100lg/L.
Explanations for the lowUIC in iodine supplement usersmight
be that the supplements were not consumed daily by all users,
or that supplemental iodine was trapped in the thyroid to refill
depleted iodine stores. The latter was indicated in a recent
study in Bangladesh in pregnant women with comparable
median UIC as in our supplement nonusers (42). Introducing a
supplement containing 250lg iodine/day did not result in an
increase in UIC.
Iodine intake and thyroid function
In ID, a range of effective autoregulatory mechanisms are
triggered in the thyroid and other tissues to maintain eu-
thyroidism. This involves a preferential secretion of T3 over
T4, whereas an elevated TSH is rarely seen in populations
with mild to moderate ID (43). In our study, we did observe
a higher FT3 when habitual iodine intake from food was
below*150lg/day (reflected in a UIC below*100lg/L),
but the trends in the FT4/FT3 ratio did not reach statistical
significance.
Our findings indicate that short-term iodine availability
(measured by UIC) might have a partially different impact on
thyroid hormones compared to long-term iodine intake
(calculated by the FFQ). For FT3, our findings, both for UIC
and for habitual iodine intake from food, indicate that a
low iodine intake (below *150lg/day) is associated with
a higher plasma FT3 (Fig. 3). This is in line with observations
in both animal and human studies and reflects the auto-
regulatory mechanisms to preserve iodine in response to
decreased availability of iodine (44). A preferential produc-
tion of T3 to T4 saves one iodine atom per hormone pro-
duced, and at the same time secures availability of most
maternal tissues to T3, the active form of thyroid hormone.
However, the fetal brain may be vulnerable to lower maternal
T4 since T3 in the fetal brain is predominantly generated
locally from maternal T4 during early pregnancy (44). Sev-
eral studies show that maternal hypothyroxinemia may result
in suboptimal fetal brain development, and that this may
particularly be the case before the onset of fetal thyroid
hormone production at mid pregnancy (45,46).
We observed that UIC was inversely associated with FT4,
which is opposite to what one might expect, and also opposite
to what was indicated for iodine intake by the FFQ (Fig. 3).
We hypothesize that this finding might reflect that thyroid
hormone production is inhibited during more acute higher
iodine availability during pregnancy via a mechanism similar
to that of the overt Wolff-Chaikoff effect. Interestingly, these
associations were already present within the range of what
is considered optimal and safe iodine intake. These results
could indicate that pregnant women with mild to moderate ID
who increase their iodine intake during pregnancy are more
prone to having a (temporary) low FT4. This is supported by
FIG. 4. Prevalence of thyroid antibody positivity by UIC (column 1; n = 2900), creatinine-adjusted UIC (column 2;
n = 2900), and by iodine from food (column 2, restricted to nonusers of iodine supplements; n= 1730), adjusted models.
Antibody positivity was defined as antibody plasma concentration >92nd percentile.
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our finding that a recent introduction of iodine-containing
supplements (GW13 or later) was associated with lower FT4,
whereas longer term use, was not (Fig. 5). Furthermore, a
similar effect was indicated in two longitudinal non-
randomized studies exploring the impact of iodine supple-
ment initiated early in pregnancy on thyroid function in mild
to moderately ID populations by Moleti et al. (median UIC
*60 lg/L in nonsupplemented women) (21,47). Also, Re-
bagliato et al. reported increased risk of elevated TSH in
pregnant women taking supplements containing 200lg io-
dine per day or more compared to 0–100 lg/day (22). Con-
trary to this, no difference was seen in a recent RCT of iodine
supplementation in pregnancy by Gowachirapant et al. in a
mildly ID population (median UIC 131 lg/L at baseline)
(23). Interestingly, using data from MoBa, we have previ-
ously reported that maternal iodine supplement use initiated
in the first trimester was associated with more behavior
problems in 3 year old children (3) and increased risk of
ADHD diagnosis in 6–14 year old children (4). These asso-
ciations could be explained by a temporary lower thyroid
hormone production due to an acute higher iodine availability
in this vulnerable window of neurodevelopment. Taken to-
gether, these results indicate that mild- to moderate ID should
optimally be prevented before pregnancy since initiating
supplement use in pregnancy might be too late and may have
adverse effects on thyroid function.
Several nutrients and nonnutrients are known to affect
thyroid function (8,48). We were not able to detect effect
modification on the association of iodine intake with thyroid
function by either low iron or selenium status, smoking, or
intake of cruciferous vegetables. Iron is essential for the ac-
tivity of thyroid peroxidase in the production of thyroid
hormones. Selenium is an integral part of selenoenzymes
protecting the thyroid from excess H2O2 produced in thyroid
hormone synthesis. Selenium is also incorporated in deiodi-
nase enzymes crucial for regulation of thyroid hormone ac-
tivity and thus action in target-tissues. Cruciferous vegetables
and smoking both contribute with goitrogenic compounds
inhibiting iodine uptake in the thyroid. In our study popula-
tion, the prevalence of smoking, selenium deficiency, and the
intake of cruciferous vegetables were all low limiting the
ability to explore potential effect modifications. Therefore,
we cannot conclude that such effects were not present as this
study was probably underpowered to detect such interactions.
Some studies have indicated that ID populations might be
more vulnerable to thyroid disrupting substances (48), and
that concurrent iron and/or selenium deficiency might have
synergistic effects with ID on thyroid function (49).
Strengths and limitations
The present study has several limitations. Most impor-
tantly, the participants in this study had an insufficient iodine
intake regardless of their reported food and supplement in-
take (i.e., median UIC ‡150lg/L, see Fig. 2 and Table 1).
Thus, we might lack an iodine sufficient group for compari-
son. However, the cutoff of 150 lg/L for defining inadequacy
may be too high. In the Nordic countries, the recommended
iodine intake for pregnant women of 175 lg/d is only 60% the
WHO recommendation of 250lg/d (14), corresponding to a
median UIC ‡105lg/L. Nevertheless, median UIC was be-
low 100lg/L even in the participants with the highest re-
ported iodine intake from food (Fig. 2) as well as in current
supplement users. Participants who reported use of iodine-
containing supplements all time periods from 6 months be-
fore pregnancy probably had adequate iodine status, but they
were few (n= 138).
The cross-sectional design is a limitation preventing us to
study potential intra-individual changes in thyroid function
parameters by short-term iodine availability. In addition, the
observational design means that residual confounding cannot
be ruled out. This study included a selected sample of highly
motivated mothers with offspring with low prevalence
of language delay and no autism (Fig. 1). Increased risk of
Table 2. The 2.5th and 97.5th Percentiles (Reference Range) of TSH, FT4, and FT3 in TPOAb
Negative Pregnant Women
Reference populationa Also excluding TgAb-positiveb
Plasma TSH, mU/L
n 2577 2430
2.5th percentile [95% CI] 0.39 [0.36, 0.44] 0.41 [0.36, 0.45]
Median [95% CI] 1.19 [1.17, 1.22] 1.19 [1.16, 1.22]
97.5th percentile [95% CI] 2.70 [2.62, 2.80] 2.70 [2.60, 2.79]
Plasma FT4, pmol/L
n 2576 2429
2.5th percentile [95% CI] 10.3 [10.2, 10.4] 10.3 [10.2, 10.4]
Median [95% CI] 12.6 [12.5, 12.6] 12.5 [12.5, 12.6]
97.5th percentile [95% CI] 15.6 [15.3, 16.0] 15.6 [15.3, 16.0]
Plasma FT3, pmol/L
n 2577 2430
2.5th percentile [95% CI] 4.00 [3.97, 4.03] 4.00 [3.97, 4.03]
Median [95% CI] 4.90 [4.87, 4.92] 4.90 [4.87, 4.93]
97.5th percentile [95% CI] 6.00 [5.91, 6.10] 6.00 [5.91, 6.10]
Mean gestational week, 18.5; SD, 1.3.
aPopulation characteristics: singleton pregnancies, not TPOAb positive (i.e., TPOAb <4.11 IU/mL), not current user of thyroid
medication or thyroid disrupting medication, and not in vitro fertilization.
bAdditionally excluding TgAb positive (>4.11 IU/mL according to manufacturer cutoff), n = 147.
FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyrotropin.
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language delay was previously documented in children of
mothers with low iodine intake in MoBa (3), thus potentially,
the prevalence of mothers with altered thyroid function due to
ID might be lower in our study sample. Substantial mea-
surement error of the exposure variables in measuring actual
iodine intake probably also contributed to an attenuation of
the associations. Although the total number of participants
was large, there was limited power to study potential effect
modifications by iron status, selenium status, smoking, and
goitrogens in cruciferous vegetables.
Strengths of the study include the relatively large number
of participants, the substantial variation in iodine intake,
having two different measures of iodine intake (i.e., one for
habitual intake and one for short-term intake) and the ex-
tensive data collection allowing us to adjust for many con-
founding factors.
Clinical relevance and implications
Overall, the findings in this study indicate that a habitual
iodine intake below approximately 150lg/day is associated
with changes in maternal thyroid hormone concentrations in
pregnancy but not with significant differences in the refer-
ence range limits. Many studies have demonstrated that the
Table 3. The 2.5th and 97.5th Percentiles of TSH, FT4, and FT3 by Measures of Iodine Status
(Adjusted Models)
UIC, lg/L
<30 30–59.9 60–99.9 100–150 >150 p-Valuea
n 507 625 629 444 372
UIC, median (IQR), lg/L 20 (14, 25) 44 (37, 51) 78 (69, 88) 121 (110, 135) 195 (167, 260)
Plasma TSH, mU/L
2.5th percentile [95% CI] 0.48 [0.39, 0.58] 0.40 [0.32, 0.49] 0.37 [0.29, 0.45] 0.39 [0.29, 0.49] 0.36 [0.25, 0.46] 0.36
97.5th percentile [95% CI] 2.54 [2.32, 2.76] 2.57 [2.36, 2.77] 2.82 [2.61, 3.02] 2.76 [2.52, 3.00] 2.87 [2.60, 3.13] 0.16
Plasma FT4, pmol/L
2.5th percentile [95% CI] 10.4 [10.2, 10.6] 10.6 [10.4, 10.7] 10.4 [10.2, 10.6] 10.4 [10.2, 10.7] 10.2 [10.0, 10.5] 0.29
97.5th percentile [95% CI] 15.9 [14.9, 16.9] 15.6 [14.7, 16.5] 16.2 [15.3, 17.1] 15.2 [14.2, 16.3] 15.2 [14.0, 16.4] 0.58
Plasma FT3, pmol/L
2.5th percentile [95% CI] 4.14 [4.04, 4.24] 4.08 [3.98, 4.17] 4.07 [3.98, 4.16] 4.05 [3.94, 4.15] 4.02 [3.90, 4.15] 0.62
97.5th percentile [95% CI] 6.08 [5.89, 6.26] 5.90 [5.73, 6.06] 5.92 [5.75, 6.10] 5.97 [5.77, 6.17] 5.77 [5.55, 5.98] 0.30
Creatinine-adjusted UIC (UIC*Cr), lg/L
<45 45–69.9 70–89.9 90–130 >130 p-Valuea
n 428 700 580 459 410
UIC*Cr, median (IQR), lg/L 30 (20, 38) 60 (53, 65) 78 (73, 83) 105 (97, 116) 172 (143, 227)
Plasma TSH, mU/L
2.5th percentile [95% CI] 0.47 [0.36, 0.58] 0.40 [0.32, 0.48] 0.38 [0.29, 0.47] 0.39 [0.29, 0.49] 0.41 [0.30, 0.51] 0.80
97.5th percentile [95% CI] 2.56 [2.31, 2.82] 2.62 [2.42, 2.81] 2.77 [2.56, 2.99] 2.78 [2.54, 3.02] 2.78 [2.53, 3.04] 0.56
Plasma FT4, pmol/L
2.5th percentile [95% CI] 10.6 [10.4, 10.8] 10.3 [10.2, 10.5] 10.5 [10.3, 10.6] 10.4 [10.2, 10.6] 10.3 [10.1, 10.5] 0.36
97.5th percentile [95% CI] 16.0 [14.8, 17.2] 15.5 [14.6, 16.4] 16.2 [15.3, 17.2] 15.6 [14.6, 16.7] 15.3 [14.2, 16.5] 0.72
Plasma FT3, pmol/L
2.5th percentile [95% CI] 4.14 [4.01, 4.28] 4.09 [3.99, 4.20] 4.06 [3.94, 4.17] 4.08 [3.95, 4.21] 4.02 [3.89, 4.16] 0.77
97.5th percentile [95% CI] 6.05 [5.80, 6.29] 5.95 [5.77, 6.13] 5.97 [5.77, 6.17] 5.84 [5.62, 6.06] 5.82 [5.58, 6.05] 0.61
Iodine from food, lg/day (restricted to supplement nonusers)
<100 100–150 >150 p-Valuea
n 523 562 457
Iodine intake, median (IQR), lg/day 77 (62, 89) 123 (111, 135) 183 (163, 217)
Plasma TSH, mU/L
2.5th percentile [95% CI] 0.49 [0.40, 0.59] 0.41 [0.32, 0.49] 0.43 [0.33, 0.53] 0.20
97.5th percentile [95% CI] 2.70 [2.35, 3.05] 2.78 [2.46, 3.09] 2.61 [2.24, 2.99] 0.74
Plasma FT4, pmol/L
2.5th percentile [95% CI] 10.3 [10.1, 10.6] 10.5 [10.3, 10.7] 10.5 [10.2, 10.7] 0.47
97.5th percentile [95% CI] 16.1 [15.1, 17.0] 15.4 [14.6, 16.3] 15.4 [14.3, 16.4] 0.35
Plasma FT3, pmol/L
2.5th percentile [95% CI] 4.06 [3.93, 4.19] 4.07 [3.95, 4.19] 4.08 [3.94, 4.22] 0.94
97.5th percentile [95% CI] 6.03 [5.82, 6.24] 5.88 [5.71, 6,06] 5.90 [5.70, 6.11] 0.30
Data from adjusted models: patients with TPOAb positive (TPOAb >4.11 IU/mL) and current users of thyroid medication or thyroid
disrupting medication, and women who have undergone in vitro fertilization were excluded.
Values are from quantile regression and adjusted for maternal age, prepregnancy BMI, gestational age at sampling, urinary creatinine
(when UIC*Cr is the exposure), and energy intake (when iodine from food is the exposure). Results from crude models are reported in
Supplementary Table S2.
ap-Value from quantile regression.
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developing fetus might be vulnerable to maternal thyroid
hormone supply, particularly in the first half of pregnancy
(45). Only 30% of the MoBa women reached an iodine intake
from food sources of 150 lg/day, which is equivalent to the
recommended intake for nonpregnant women.
Current international guidelines recommend that gesta-
tional thyroid function reference ranges are calculated in an
iodine-sufficient population. To our knowledge, there are no
studies that have shown that thyroid function reference ran-
ges during pregnancy differ according to iodine status. Our
results indicate that mild iodine deficiency is not a determi-
nant of thyroid function reference ranges during pregnancy
and that valid thyroid function reference ranges can be
ascertained also in populations classified as being mildly to
moderately iodine deficient. However, this finding needs to
be confirmed in other studies before changing the guidelines.
We also found that initiating iodine supplement use in
pregnancy in a population with mild to moderate ID diets
was associated with lower FT4, which may be harmful for
the developing child. Thus, this study provides further sup-
porting evidence to the recommendation by the WHO that
strategies to prevent iodine deficiency should target thewhole
population, and in particular all women of childbearing age,
so that an adequate iodine status is secured well before
conception. Today, there is a lack of evidence to support
recommending iodine supplements for pregnant women in
mild to moderately iodine deficient populations (5,20).
Conclusion
All in all, the results indicate that mild to moderate iodine
deficiency is associated with thyroid hormone levels in
pregnancy. However, the changes were small, suggesting that
normal reference ranges can be determined based on data also
from mildly iodine deficient populations, but this must be
confirmed in other studies. Introducing an iodine-containing
supplement might temporarily inhibit thyroid hormone pro-
duction and/or release, thus ID should ideally be prevented
before conception.
Acknowledgments
We are grateful to all the participating families in
Norway who take part in this on-going cohort study. The
Norwegian Mother and Child Cohort Study is supported by
the Norwegian Ministry of Health and the Ministry of
Education and Research, National Institutes of Health/Na-
tional Institute of Environmental Health Sciences (contract
No. N01-ES-75558), National Institutes of Health/National
Institute of Neurological Disorders and Stroke (grant Nos.
UO1 NS 047537-01 and UO1 NS 047537-06A1). M.H.A.
FIG. 5. Timing of initiation of iodine-containing supplements in pregnancy and measures of maternal thyroid function,
adjusted models. Timing was categorized as: no reported supplement use (never; n= 1738), first use in weeks 1–26 before
conception (preconception; n = 347), first use during first trimester (GW 0–12; n = 323), and first use during second trimester
(GW 13–20; n = 194). Participants who reported use of iodine-containing supplements in the FFQ but did not report timing
of use (n = 308) were not included in this analysis. For TSH, the geometric mean was modelled (by square root transfor-
mation), and for FT3 and FT4 the highest first percentile was excluded to obtain *normal distribution. Crude models are
included in Supplementary Fig. S10, and models excluding antibody positive women in Supplementary Fig. S9. *p < 0.05.
GW, gestational week.
IODINE INTAKE AND THYROID FUNCTION IN PREGNANCY 1369
was supported by a four-year grant from the Norwegian
Research Council (grant No. 241430) and the Norwegian
dairy company TINE SA.
Author Disclosure Statement
M.H. Abel is employed by a Norwegian dairy company
(TINE SA), and she participates in this project as an industrial
PhD student financed partly by the dairy company and partly
by The Research Council of Norway. This project is de-
signed, owned, and administered by The Norwegian Institute
of Public Health and analysis of the data follow from pro-
tocol. All results of analyses in the project are to be published
regardless of the results. The dairy company supports the
study to raise awareness on the importance of iodine and to
gain more knowledge about the potential health effects of
milk in the Norwegian diet. Apart from M.H.A., no one from
the dairy company has been involved in the study, and in
itself, the company had no direct influence on the analysis
and interpretation of the results. All remaining authors de-
clare no competing financial interests.
References
1. Bath SC, Steer CD, Golding J, Emmett P, Rayman MP
2013 Effect of inadequate iodine status in UK pregnant
women on cognitive outcomes in their children: results
from the Avon Longitudinal Study of Parents and Children
(ALSPAC). Lancet 382:331–337.
2. Hynes KL, Otahal P, Burgess JR, Oddy WH, Hay I 2017
Reduced educational outcomes persist into adolescence
following mild iodine deficiency in utero, despite adequacy
in childhood: 15-Year follow-up of the Gestational Iodine
Cohort investigating auditory processing speed and work-
ing memory. Nutrients 9:pii:E1354.
3. Abel MH, Caspersen IH, Meltzer HM, Haugen M, Bran-
dlistuen RE, Aase H, Alexander J, Torheim LE, Brantsaeter
AL 2017 Suboptimal maternal iodine intake is associated
with impaired child neurodevelopment at 3 years of age in
the Norwegian Mother and Child Cohort Study. J Nutr 147:
1314–1324.
4. Abel MH, Ystrom E, Caspersen IH, Meltzer HM, Aase H,
Torheim LE, Askeland RB, Reichborn-Kjennerud T,
Brantsaeter AL 2017 Maternal iodine intake and offspring
attention-deficit/hyperactivity disorder: Results from a
large prospective cohort study. Nutrients 9.
5. Pearce EN, Lazarus JH, Moreno-Reyes R, Zimmermann
MB 2016 Consequences of iodine deficiency and excess in
pregnant women: an overview of current knowns and un-
knowns. Am J Clin Nutr 104:918S–923S.
6. Redman K, Ruffman T, Fitzgerald P, Skeaff S 2016 Iodine
deficiency and the brain: Effects and mechanisms. Crit Rev
Food Sci Nutr 56:2695–2713.
7. Aburto N, Abudou M, Candeias V, Wu T 2014 Effect and
safety of salt iodization to prevent iodine deficiency disorders:
a systematic review with meta-analyses. In: World Health
Organization [WHO] eLibrary of Evidence for Nutrition
Actions (eLENA). World Health Organization, Geneva.
8. O’Kane SM, Mulhern MS, Pourshahidi LK, Strain JJ, Yeates
AJ 2018 Micronutrients, iodine status and concentrations of
thyroid hormones: a systematic review. Nutr Rev 76:418–431.
9. Roman GC 2007 Autism: transient in utero hypothyroxinemia
related to maternal flavonoid ingestion during pregnancy and
to other environmental antithyroid agents. J Neurol Sci
262:15–26.
10. Shi X, Han C, Li C, Mao J, Wang W, Xie X, Li C, Xu B,
Meng T, Du J, Zhang S, Gao Z, Zhang X, Fan C, Shan Z,
Teng W 2015 Optimal and safe upper limits of iodine in-
take for early pregnancy in iodine-sufficient regions: a
cross-sectional study of 7190 pregnant women in China. J
Clin Endocrinol Metab 100:1630–1638.
11. Laurberg P, Cerqueira C, Ovesen L, Rasmussen LB, Perrild
H, Andersen S, Pedersen IB, Carle A 2010 Iodine intake as
a determinant of thyroid disorders in populations. Best
Pract Res Clin Endocrinol Metab 24:13–27.
12. Andersson M, de Benoist B, Delange F, Zupan J 2007
Prevention and control of iodine deficiency in pregnant and
lactating women and in children less than 2-years-old:
conclusions and recommendations of the technical consul-
tation. Public Health Nutr 10:1606–1611.
13. EFSA NDA Panel (EFSA Panel on Dietetic Products Nu-
trition and Allergies) 2014 Scientific opinion on dietary
reference values for iodine. EFSA J 12:3660.
14. NNR12 Project Group 2014 Iodine in Nordic Nutrition
Recommendations 2012, Integrating Nutrition and Physical
Activity. Fifth edition. Nordic Council of Ministers, Co-
penhagen, pp 583–590.
15. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H,
Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel
SJ, Peeters RP, Sullivan S 2017 2017 Guidelines of the
American Thyroid Association for the diagnosis and man-
agement of thyroid disease during pregnancy and the
postpartum. Thyroid 27:315–389.
16. Food and Nutrition Board, Institute of Medicine 2001 Io-
dine dietary reference intakes for vitamin A, vitamin K,
arsenic, boron, chromium, copper, iodine, iron, manganese,
molybdenum, nickel, silicon, vanadium, and zinc. National
Academies Press, Washington (DC), 258–289.
17. Korevaar TIM, Medici M, Visser TJ, Peeters RP 2017
Thyroid disease in pregnancy: new insights in diagnosis
and clinical management. Nat Rev Endocrinol 13:610–622.
18. World Health Organization, United Nations Children’s
Fund, International Council for Control of Iodine Deficiency
Disorders 2007 Assessment of Iodine Deficiency Disorders
and Monitoring Their Elimination: A Guide for Programme
Managers. Third edition. WHO, Geneva, Switzerland.
19. Becker DV, Braverman LE, Delange F, Dunn JT, Franklyn
JA, Hollowell JG, Lamm SH, Mitchell ML, Pearce E, Rob-
bins J, Rovet JF 2006 Iodine supplementation for pregnancy
and lactation-United States and Canada: recommendations of
the American Thyroid Association. Thyroid 16:949–951.
20. Harding KB, Pena-Rosas JP, Webster AC, Yap CM, Payne
BA, Ota E, De-Regil LM 2017 Iodine supplementation for
women during the preconception, pregnancy and postpar-
tum period. Cochrane Database Syst Rev 3:CD011761.
21. Moleti M, Di Bella B, Giorgianni G, Mancuso A, De Vivo A,
Alibrandi A, Trimarchi F, Vermiglio F 2011 Maternal thyroid
function in different conditions of iodine nutrition in pregnant
women exposed to mild-moderate iodine deficiency: an ob-
servational study. Clin Endocrinol (Oxf) 74:762–768.
22. Rebagliato M, Murcia M, Espada M, Alvarez-Pedrerol M,
Bolumar F, Vioque J, Basterrechea M, Blarduni E, Ramon
R, Guxens M, Foradada CM, Ballester F, Ibarluzea J,
Sunyer J 2010 Iodine intake and maternal thyroid function
during pregnancy. Epidemiology 21:62–69.
23. Gowachirapant S, Jaiswal N, Melse-Boonstra A, Galetti V,
Stinca S, Mackenzie I, Thomas S, Thomas T, Winichagoon
1370 ABEL ET AL.
P, Srinivasan K, Zimmermann MB 2017 Effect of iodine
supplementation in pregnant women on child neurodeve-
lopment: a randomised, double-blind, placebo-controlled
trial. Lancet Diabetes Endocrinol 5:853–863.
24. Taylor PN, Okosieme OE, Dayan CM, Lazarus JH 2014
Therapy of endocrine disease: Impact of iodine supple-
mentation in mild-to-moderate iodine deficiency: systematic
review and meta-analysis. Eur J Endocrinol 170:R1–R15.
25. Zhou SJ, Anderson AJ, Gibson RA, Makrides M 2013 Effect
of iodine supplementation in pregnancy on child develop-
ment and other clinical outcomes: a systematic review of
randomized controlled trials. Am J Clin Nutr 98:1241–1254.
26. Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E,
Daltveit AK, Handal M, Haugen M, Hoiseth G, Knudsen
GP, Paltiel L, Schreuder P, Tambs K, Vold L, Stoltenberg
C 2016 Cohort profile update: The Norwegian Mother and
Child Cohort Study (MoBa). Int J Epidemiol 45:382–388.
27. Irgens LM 2000 The Medical Birth Registry of Norway.
Epidemiological research and surveillance throughout 30
years. Acta Obstet Gynecol Scand 79:435–439.
28. Meltzer HM, Brantsaeter AL, Ydersbond TA, Alexander J,
Haugen M 2008 Methodological challenges when moni-
toring the diet of pregnant women in a large study: expe-
riences from the Norwegian Mother and Child Cohort
Study (MoBa). Matern Child Nutr 4:14–27.
29. Norwegian Institute of Public Health website, MoBa Food
Frequency Questionnaire (English translation). Available at:
www.webcitation.org/6u5JMPcZg (accessed October 9,
2017).
30. Dahl L, Johansson L, Julshamn K, Meltzer HM 2004 The
iodine content of Norwegian foods and diets. Public Health
Nutr 7:569–576.
31. Dahl L, Opsahl JA, Meltzer HM, Julshamn K 2003 Iodine
concentration in Norwegian milk and dairy products. Br J
Nutr 90:679–685.
32. Haugen M, Brantsaeter AL, Alexander J, Meltzer HM 2008
Dietary supplements contribute substantially to the total
nutrient intake in pregnant Norwegian women. Ann Nutr
Metab 52:272–280.
33. Brantsaeter AL, Haugen M, Alexander J, Meltzer HM 2008
Validity of a new food frequency questionnaire for preg-
nant women in the Norwegian Mother and Child Cohort
Study (MoBa). MaternChild Nutr 4:28–43.
34. Brantsaeter AL, Abel MH, Haugen M, Meltzer HM 2013
Risk of suboptimal iodine intake in pregnant Norwegian
women. Nutrients 5:424–440.
35. Brantsaeter AL, Haugen M, Hagve TA, Aksnes L, Ras-
mussen SE, Julshamn K, Alexander J, Meltzer HM 2007
Self-reported dietary supplement use is confirmed by bio-
logical markers in the Norwegian Mother and Child Cohort
Study (MoBa). Ann Nutr Metab 51:146–154.
36. Brantsaeter AL, Haugen M, Julshamn K, Alexander J,
Meltzer HM 2009 Evaluation of urinary iodine excretion as
a biomarker for intake of milk and dairy products in
pregnant women in the Norwegian Mother and Child Co-
hort Study (MoBa). Eur J Clin Nutr 63:347–354.
37. Ronningen KS, Paltiel L, Meltzer HM, Nordhagen R,
Lie KK, Hovengen R, Haugen M, Nystad W, Magnus P,
Hoppin JA 2006 The biobank of the Norwegian Mother and
Child Cohort Study: a resource for the next 100 years. Eur J
Epidemiol 21:619–625.
38. Willett WC, Howe GR, Kushi LH 1997 Adjustment for
total energy intake in epidemiologic studies. Am J Clin
Nutr 65:1220S–1228S; discussion 1229S–1231S.
39. Murcia M, Espada M, Julvez J, Llop S, Lopez-Espinosa MJ,
Vioque J, Basterrechea M, Riano I, Gonzalez L, Alvarez-
Pedrerol M, Tardon A, Ibarluzea J, Rebagliato M 2018 Io-
dine intake from supplements and diet during pregnancy and
child cognitive and motor development: the INMA Mother
and Child Cohort Study. J Epidemiol Community Health
72:216–222.
40. Korevaar TIM, Pop VJ, Chaker L, Goddijn M, de Rijke YB,
Bisschop PH, Broeren MA, Jaddoe VWV, Medici M, Visser
TJ, Steegers EAP, Vrijkotte TG, Peeters RP 2018 Dose-
dependency and a functional cut-off for TPO-antibody
positivity during pregnancy. J Clin Endocrinol Metab 103:
778–789.
41. Buis M 2013 Postrcspline: Stata module containing post-
estimation commands for models using a restricted cubic
spline. Statistical Software Components S456928, Boston
College Department of Economics, revised 13 Dec 2013.
Available at: https://econpapers.repec.org/software/bocbo
code/s456928.htm (accessed September 8, 2017).
42. Mridha MK, Matias SL, Paul RR, Hussain S, Khan MSA,
Siddiqui Z, Ullah B, Sarker M, Hossain M, Young RT,
Arnold CD, Dewey KG 2017 Daily consumption of lipid-
based nutrient supplements containing 250 mug iodine does
not increase urinary iodine concentrations in pregnant and
postpartum women in Bangladesh. J Nutr 147:1586–1592.
43. de Escobar GM, Obregon MJ, del Rey FE 2007 Iodine
deficiency and brain development in the first half of preg-
nancy. Public Health Nutr 10:1554–1570.
44. Obregon MJ, Escobar del Rey F, Morreale de Escobar G
2005 The effects of iodine deficiency on thyroid hormone
deiodination. Thyroid 15:917–929.
45. Velasco I, Bath SC, Rayman MP 2018 Iodine as essential
nutrient during the first 1000 days of life. Nutrients 10:E290.
46. Levie D, Korevaar TIM, Bath SC, Dalmau-Bueno A,
Murcia M, Espada M, Dineva M, Ibarluzea JM, Sunyer
J, Tiemeier H, Rebagliato M, Rayman MP, Peeters RP,
Guxens M 2018 Thyroid function in early pregnancy, child
IQ, and autistic traits: a meta-analysis of individual-
participant data. J Clin Endocrinol Metab 103:2967–2979.
47. Moleti M, Lo Presti VP, Campolo MC, Mattina F, Galletti M,
Mandolfino M, Violi MA, Giorgianni G, De Domenico D,
Trimarchi F,Vermiglio F2008 Iodine prophylaxis using iodized
salt and risk of maternal thyroid failure in conditions of mild
iodine deficiency. J Clin Endocrinol Metab 93:2616–2621.
48. Mughal BB, Fini JB, Demeneix BA 2018 Thyroid-disrupting
chemicals and brain development: an update. Endocr Connect
7:R160–R186.
49. Hess SY 2010 The impact of common micronutrient defi-
ciencies on iodine and thyroid metabolism: the evidence
from human studies. Best Pract Res Clin Endocrinol Metab
24:117–132.
Address correspondence to:
Anne Lise Brantsæter, PhD
Department of Environmental Exposure
and Epidemiology
Division of Infection Control and Environmental Health
Norwegian Institute of Public Health
P.O. Box 4404
Oslo NO-0403
Norway
E-mail: annelise.brantsaeter@fhi.no
IODINE INTAKE AND THYROID FUNCTION IN PREGNANCY 1371
